Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, ...

Mental health has not always been talked about within communities of color, but that is starting to shift because of people ...

The latest update from the National Hurricane Center now shows a medium chance of development near Florida or along the ...

Many of the traditions we know today began in postwar America — including the very color of many modern wedding dresses.

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

Depression among dads is not always central to mental health discussions. But new research underscores how important it is to ...

Mark Duplass, best known as Chip Black on the Apple TV+ series, recently opened up about his long and personal journey with mental health.

Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder.

Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA, the ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...